EGFR-TKI resistance by BIM polymorphism was circumvented when combined with HDAC inhibition [64], and antitumour activity of histone deacetylase inhibitors was observed in NSCLC cells [65]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.